BiotechTube

ERAS-0015 + ERAS-0015 in combination

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Solid Tumors

Conditions

Metastatic Solid Tumors

Trial Timeline

Jun 5, 2025 → Dec 1, 2028

NCT ID
NCT06983743

About ERAS-0015 + ERAS-0015 in combination

ERAS-0015 + ERAS-0015 in combination is a phase 1 stage product being developed by Erasca for Metastatic Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06983743. Target conditions include Metastatic Solid Tumors.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06983743Phase 1Recruiting

Competing Products

20 competing products in Metastatic Solid Tumors

See all competitors
ProductCompanyStageHype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
44
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
25
AbemaciclibEli LillyPre-clinical
23
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
77
SYNB1891 + AtezolizumabSynlogicPhase 1
25
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 3
77
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 1/2
41
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
33
Induction therapyChugai PharmaceuticalPhase 2
52
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
Paclitaxel + Bevacizumab + Letrozole + Anastrozole + Exemestane + Fulvestrant + Goserelin + leuprorelinChugai PharmaceuticalPhase 2
52
bevacizumab + PaclitaxelChugai PharmaceuticalPhase 2
52
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
52
GC33Chugai PharmaceuticalPhase 1
33
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
77
DS9051bDaiichi SankyoPhase 1
33

Other Products from Erasca

Naporafenib + Dacarbazine + Temozolomide + TrametinibPhase 3
74
ERAS-007 + ERAS-601Phase 1/2
38
ERAS-007 + Encorafenib + Cetuximab + PalbociclibPhase 1/2
38
ERAS-007 + ERAS-601 + GilteritinibPhase 1/2
38
ERAS-601 + Cetuximab + PembrolizumabPhase 1
30